Chemotherapy in Pancreatic Cancer: A Systematic Review

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2018 Oct 23

PMID 30344279

Citations 35

Authors

Leva Hajatdoost

Keyvan Sedaghat

Erin J Walker

Jackson Thomas

Sam Kosari

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy.

Materials And Methods: Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared.

Results: In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection (46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Amongst studies that investigated second-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months).

Conclusions: There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.

Citing Articles

S-1/irinotecan/oxaliplatin chemotherapy achieved a pathological complete remission in advanced pancreatic carcinoma.

Chen R, Iwai T, Tajima H, Adachi K, Okuwaki K, Watanabe M Clin J Gastroenterol. 2024; 18(1):220-223.

PMID: 39503980 DOI: 10.1007/s12328-024-02055-1.

Recent Developments in Nanotechnology and Immunotherapy for the Diagnosis and Treatment of Pancreatic Cancer.

Sindhi K, Kanugo A Curr Pharm Biotechnol. 2024; 26(2):143-168.

PMID: 38415488 DOI: 10.2174/0113892010284407240212110745.

Study of the antioxidant and anti-pancreatic cancer activities of aqueous extracts obtained by maceration and ultrasonic extraction techniques.

Chebaro Z, Abdallah R, Badran A, Hamade K, Hijazi A, Maresca M Front Pharmacol. 2023; 14:1201969.

PMID: 37593172 PMC: 10427766. DOI: 10.3389/fphar.2023.1201969.

Adjuvant gemcitabine after resection of pancreatic cancer without significant difference in overall survival: a retrospective cohort study.

Bauer K, Buchler P, Henne-Bruns D, Manzini G Ann Med Surg (Lond). 2023; 85(7):3284-3290.

PMID: 37427179 PMC: 10328665. DOI: 10.1097/MS9.0000000000000854.

EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4.

Li H, Wang H, Cui Y, Jiang W, Zhan H, Feng L Hereditas. 2023; 160(1):23.

PMID: 37198697 PMC: 10190069. DOI: 10.1186/s41065-023-00280-1.

References

Herman J, Chang D, Goodman K, Dholakia A, Raman S, Hacker-Prietz A . Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2014; 121(7):1128-37. PMC: 4368473. DOI: 10.1002/cncr.29161. View

Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y . Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016; 77(3):595-603. DOI: 10.1007/s00280-016-2972-3. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M . A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol. 2015; 27(3):502-8. PMC: 4769993. DOI: 10.1093/annonc/mdv603. View

Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S . Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. Eur J Cancer. 2016; 54:96-103. DOI: 10.1016/j.ejca.2015.11.002. View

Kumar J, Reccia I, Sodergren M, Kusano T, Zanellato A, Pai M . Radiofrequency assisted pancreaticoduodenectomy for palliative surgical resection of locally advanced pancreatic adenocarcinoma. Oncotarget. 2018; 9(21):15732-15739. PMC: 5884660. DOI: 10.18632/oncotarget.24596. View

Goldstein D, El-Maraghi R, Hammel P, Heinemann V, Kunzmann V, Sastre J . nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015; 107(2). DOI: 10.1093/jnci/dju413. View

Kordes S, Klumpen H, Weterman M, Schellens J, Richel D, Wilmink J . Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015; 75(6):1135-41. PMC: 4441736. DOI: 10.1007/s00280-015-2730-y. View

10.

Postlewait L, Ethun C, Kooby D, Sarmiento J, Chen Z, Staley 3rd C . Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. J Surg Oncol. 2016; 114(3):336-41. DOI: 10.1002/jso.24317. View

11.

Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J . A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford). 2015; 17(7):587-93. PMC: 4474505. DOI: 10.1111/hpb.12413. View

12.

Wu Z, Gabrielson A, Hwang J, Pishvaian M, Weiner L, Zhuang T . Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015; 76(6):1309-14. DOI: 10.1007/s00280-015-2855-z. View

13.

Sherman W, Chu K, Chabot J, Allendorf J, Schrope B, Hecht E . Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 2014; 121(5):673-80. DOI: 10.1002/cncr.29112. View

14.

Belli C, Piemonti L, DIncalci M, Zucchetti M, Porcu L, Cappio S . Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015; 77(3):477-84. DOI: 10.1007/s00280-015-2932-3. View

15.

Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M . Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017; 116(4):464-471. PMC: 5318973. DOI: 10.1038/bjc.2016.436. View

16.

Goji T, Kimura T, Miyamoto H, Takehara M, Kagemoto K, Okada Y . A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015; 76(3):615-20. DOI: 10.1007/s00280-015-2835-3. View

17.

Chan K, Shah K, Lien K, Coyle D, Lam H, Ko Y . A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One. 2014; 9(10):e108749. PMC: 4186762. DOI: 10.1371/journal.pone.0108749. View

18.

Shimoda M, Kubota K, Shimizu T, Katoh M . Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. Br J Surg. 2015; 102(7):746-54. DOI: 10.1002/bjs.9775. View

19.

Catenacci D, Junttila M, Karrison T, Bahary N, Horiba M, Nattam S . Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015; 33(36):4284-92. PMC: 4678179. DOI: 10.1200/JCO.2015.62.8719. View

20.

Wang J, Wu C, Yeh Y, Shyr Y, Wu Y, Kuo C . Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015; 6(20):18162-73. PMC: 4627242. DOI: 10.18632/oncotarget.4216. View